GetSeriousOK
8時間前
In that first webcast, Mayer was kind of a Chatty Cathy. It started badly -- they had trouble getting it online so it didn't start on time, and Bobby had two devices connected, creating a really annoying echo. When Mayer started talking, he wasn't comfortable. He forged ahead, though. I don't think he was quite as informal and personal in the second webcast -- didn't watch it.
When you ask "Do you seriously think Kelly offfered [sic] a distributor her own position?" I would answer with "The CEO position? Absolutely, because Mayer said so, and I believe him."
When you ask "Do you think Rick offered him Kelly’s job?" you make it sound like you think Rick runs this company. The CEO job is not Rick's to offer. Kelly runs this company, lock stock and barrel. She took control when her dad died and she isn't going to relinquish control.
I'm guessing that Rick and Kelly decided it would be a good idea, and since their two votes are a majority on the BOD, it doesn't matter what Koneru thinks. He's just there to fill the required third seat.
You need to ask yourself, though: who would want that CEO job? The CEO would have to ask Kelly and Rick for permission to do ANYTHING and if the company failed the CEO would get the blame even though it would not be the CEO's fault. And did I mention that it's an unpaid position?
I don't think you realize, or will admit, how close BIEL is to filing for BK. It's been insolvent since inception. Better companies than THIS have gone BK. Mayer is no fool. Being CEO of this company would be like sitting in a dunk tank at the carnival. If you have nothing else, well it's a job, sort of.
Now if Mayer could take control of the BIEL BOD, he might have something. He needs money in a serious, almost DESPERATE, way. When Mayer gets his StartEngine campaign online, I think he's going to discover that BIEL shareholders don't have much money they're willing to throw at Electrome. He's hoping for $$$ millions but If he gets $300,000 I think he'll be fortunate.
Which means I don't think you realize, or will admit, how close Electrome is to tossing in the towel. I think they'll buy 25,000 units from Kelly and try to sell them... but without $$$ millions in funding for marketing and advertising and infrastructure, Electrome is going to have a hard time selling 25,000 units.
Haha aren't you glad you asked me what I think?
BIEL
GetSeriousOK
9時間前
Mayer said in the first webcast that he was offered the CEO job and he turned it down. Ask your pumper friends who were also there - they heard it too. OR ask Mayer -- he's relatively transparent.
As for what I THINK -- you don't really care what I THINK, but I'll answer anyway. I think that being CEO of BIEL without controlling the BOD would be a truly shitty job, and not just because there's no salary. Nobody would want that job, other than someone who had absolutely nothing else going on in their career, and that doesn't describe Mayer.
I think that if Mayer could gain control of BIEL's BOD he could use the ticker to fund his venture, and Kelly/Rick/Lauren could get their money back. That would be a huge WIN for Mayer and for Kelly/Rick/Lauren, but a huge DISASTER for existing BIEL shareholders.
Don't worry though, because Kelly is too ignorant/stubborn/incompetent to do it.
Oh, BTW, Mayer also stated that he and Electrome are not buying or holding any BIEL stock.
BIEL
3331
9時間前
BIEL PATH (4 PR's) TO COPPER
The PR released a few days ago did not move the PPS because it did not provide any new information (other than confirming the PO and that manufacturing has commenced). The following four PR's released in sequence every week or two, would get us to COPPER, which would instantly strengthen BIEL and Electrome's ability to secure funding by improving valuation, leverage, credibility and investor confidence.
Below is the 4-PR Momentum Engine.
PR #1 — The “Numbers Hit the Table” PR
Timing: Immediately
Purpose: Convert the vague “initial purchase order” into a real catalyst.
Headline:
Electrome Issues $X Initial Purchase Order to BioElectronics as Commercial Launch Buildout Accelerates
Key Elements:
Actual PO dollar value
Unit count
Confirmation that this is the first of multiple scheduled orders
Manufacturing capacity expansion
Confirmation of Electrome’s launch timeline (e.g., “Q3 rollout”)
A quote from Electrome confirming reorder expectations
Why this moves PPS:
It transforms “manufacturing underway” into quantified demand, which the current PR does not provide.
PR #2 — The “Channel Expansion” PR
Timing: 5–10 days after PR #1
Purpose: Show that Electrome isn’t just marketing — they’re placing BIEL into real distribution channels.
Headline:
Electrome Secures Initial Retail & Digital Distribution Channels for ActiPatch Rollout
Key Elements:
Confirm 1–3 named channels (even small ones)
Confirm Electrome’s ecommerce platform launch date
Confirm integration into Electrome’s AI-native consumer funnel
Mention early demand indicators (waitlist signups, pre-launch interest, etc.)
Why this moves PPS:
It shows traction, not just “preparing” or “building” — which is all the current PR says .
PR #3 — The “Clinical / Regulatory Leverage” PR
Timing: 7–14 days after PR #2
Purpose: Add legitimacy and widen the addressable market.
Headline:
BioElectronics Expands Clinical & Regulatory Positioning to Support Electrome’s National Rollout
Key Elements:
New clinical data summary
New application areas (e.g., post-operative, chronic pain, sports recovery)
Any regulatory updates (EU, Canada, VA, etc.)
A statement tying this directly to Electrome’s marketing strategy
Why this moves PPS:
It reframes BIEL as a validated medical technology, not just a consumer gadget.
The current PR mentions FDA clearance but adds no new clinical or regulatory substance.
PR #4 — The “Launch Activation” PR
Timing: 10–20 days after PR #3
Purpose: Deliver the big catalyst — the one that creates the breakout.
Headline:
Electrome Launches National AI-Driven Consumer Campaign for ActiPatch With Multi-Channel Rollout
Key Elements:
Official launch date
Marketing budget range
Influencer / partnership confirmations
Early sales data (even small numbers move PPS)
Confirmation of reorder pipeline
Quotes from both CEOs about scaling
Why this moves PPS:
This is the activation event — the moment the market sees:
real demand
real marketing
real revenue
real scale
The current PR only says Electrome is “preparing” and “building” these systems, not launching them .
Optional PR #5 — The “Momentum Amplifier”
Timing: 3–7 days after PR #4
Purpose: Sustain the breakout.
Headline:
BioElectronics Reports Surge in Consumer Demand Following Electrome Launch Campaign
Key Elements:
Early sales velocity
Conversion rates
Reorder rate
Customer satisfaction metrics
Testimonials
Electrome’s next-phase marketing plans
Why this moves PPS:
It confirms the launch wasn’t a one-day event — it’s a trend.
Why This Sequence Works
Because it fixes the exact weaknesses in the PR released a few days ago:
No numbers
No scale
No timelines
No channels
No launch date
No revenue visibility
No clinical expansion
No traction metrics
Each PR in the sequence adds one missing piece until the market has a complete, investable story.
A LITTLE SPARK LAUNCHES A SUPPLY SQUEEZE
Just before the close yesterday, Level 2 showed the structural setup for a violent gap-up: Only 37M left @ .0004 and very thin above (1M @ .0005, then nothing until 5M @ .0016). Compare this to nearly 300M @ .0002 just months ago.
The wall is gone. The fuse is lit.
MOMENTUM
It blows my mind that I was loading millions at .0001 back in July 2024. Watching this momentum build and seeing a 400% PPS surge recently has been incredible. Huge thanks to everyone who helped me scoop up those .0001 and .0002 shares. And honestly… I love the bashers. They’re the useful idiots that made it possible. Keep up the good work, I’m still buying! WATCH AND LEARN!
art2426
2日前
Yeah, but the experienced and very successful CEO of SPACE X is Elon Musk. This over 20 year publicly traded corporation that has lost $41,277,336 has a first time amateur CEO with absolutely no experience running a publicly traded corporation. LOL, I wonder if ELON goes on social media to argue with stockholders.
Sorry, but comparing this company to Space X is as laughable as the one constant poster's comparisons to Netfix, Apple and Amazon.
Chartmaster
2日前
BioElectronics Advances ActiPatch Commercial Rollout With Electrome
Strategic Agreement Enters Execution Phase as Electrome Prepares AI-Enabled Consumer Campaign for FDA-Cleared, Drug-Free Pain Relief Technology
JEFFERSON, MARYLAND - June 17, 2026 (NEWMEDIAWIRE) - BioElectronics Corporation (https://www.bielcorp.com/) (OTC: BIEL), a developer of medical technology products, announces its strategic distribution and licensing agreement with Electrome Corporation has officially moved into the execution phase, and manufacturing is now underway for the launch of BioElectronics' flagship pulsed shortwave therapy as part of the Electrome PAINKILLER platform.
The partnership marks a major milestone for both companies as Electrome prepares for an aggressive consumer launch strategy designed to accelerate awareness and adoption of BioElectronics' drug-free pain therapy technologies across North America.
Electrome is currently building a comprehensive AI-native pain management platform that integrates advanced artificial intelligence, intelligent automation, predictive analytics, and high-performance digital marketing into a unified consumer ecosystem designed to rapidly scale awareness, customer acquisition, and long-term engagement with non-pharmaceutical pain management solutions.
Under the agreement, Electrome will market and distribute BioElectronics' FDA-cleared pulsed shortwave therapy products, including ActiPatch and additional products within the BioElectronics portfolio.
"We are excited to officially begin the commercial phase of this relationship with Electrome," said Kelly Whelan, President of BioElectronics Corporation. "The receipt of the initial purchase order and the commencement of manufacturing represent important operational milestones. Electrome has assembled an ambitious go-to-market strategy utilizing modern AI-driven technologies and sophisticated direct-response marketing systems that we believe position this partnership for significant growth."
Electrome's planned rollout will focus heavily on consumer education, digital outreach, scalable ecommerce infrastructure, and AI-enhanced customer engagement systems designed to streamline the consumer purchasing experience while increasing awareness of non-drug pain management solutions.
"This is an exciting moment for both organizations," said Ken Mayer, CEO of Electrome Corporation. "We believe BioElectronics' technology represents a compelling opportunity within the rapidly growing non-pharmaceutical pain management market. Our team has been preparing an advanced marketing and ecommerce ecosystem designed to support scalable growth and broad consumer adoption."
BioElectronics' pulsed shortwave therapy technology is designed to provide drug-free, non-invasive pain relief through a wearable therapy platform cleared by the U.S. FDA for the adjunctive treatment of musculoskeletal pain. The technology has been studied across multiple clinical applications and is designed for extended home use without drugs or invasive procedures.
Manufacturing activities are currently underway, with commercial launch preparations continuing across branding, ecommerce, logistics, customer support, and digital marketing initiatives.
About BioElectronics Corporation
BioElectronics Corporation is a medical device company focused on the development and commercialization of advanced bioelectronic therapies utilizing pulsed shortwave therapy technology for pain management and recovery applications. The company's product portfolio includes ActiPatch, RecoveryRx, and RecoveryRx Veterinary.
About Electrome Corporation (https://electrome.com/)
Electrome Corporation is a technology-enabled healthcare commercialization company focused on leveraging AI-driven systems, digital marketing, and advanced ecommerce infrastructure to scale innovative healthcare and wellness products in the direct-to-consumer marketplace.
Certain information set forth in this release contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects, and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
IR@bielcorp.com
View the original release on www.newmediawire.com
art2426
2日前
First of all, who is artie?. I you are referring to me, art2426, my answer is, that 400% increase in stock price you are referring to and bragging about, is as lame as it gets for finding something, anything positive to talk about for this company and your investment. That 400% gain is only because it is due to the fact that this traded at the lowest possible stock price. YES, that is what the market thought of this as an investment. And NOW it is trading at the very sad price of .0003, which is surely NOT exciting for those that have bragged about being invested in this for years at a much higher price, all the while embarrassingly pumping this on this board daily as the the stock price has plummeted down from high double zeros. --- Sound familiar who that might be?
3331
2日前
THE MONEY IS ROLLING IN! BIEL Alignment With Electrome's Retail Expansion Strategy
Electrome Corporation is positioning its flagship PAINKILLER™ platform—an AI-powered, drug-free bioelectric pain management ecosystem—for rapid commercial scaling across North America. To achieve immediate volume, Electrome has established a highly structured retail distribution and manufacturing pipeline. This strategy bypasses standard, siloed medical device adoption curves by embedding an AI care layer onto proven, FDA-cleared hardware and routing it directly through the nation's largest independent pharmacy network.
The Commercial Pipeline & Supply Chain Mechanics
The commercial rollout operates as a unified four-tier pipeline designed for immediate retail saturation and backend scale:
The Technology & Software Layer (Electrome): Electrome provides the digital infrastructure via PAINKILLER.care, an AI-guided platform that triages symptoms, automates telehealth integration, issues virtual prescriptions, and tracks patient outcomes to reduce reliance on opioids and NSAIDs.
The Hardware & Regulatory Foundation (BioElectronics Corp / BIEL): Under an exclusive licensing and distribution agreement, BIEL serves as the primary manufacturer, providing Electrome with direct access to established, FDA 510(k)-cleared hardware portfolios, extensive clinical datasets, and low-voltage electronics manufacturing.
The Logistics & Wholesale Backbone (Cencora): Distribution is handled through Cencora (formerly AmerisourceBergen), leveraging their wholesale infrastructure and their Elevate Provider Network (PSAO) to streamline billing, pharmacy integration, and supply chain logistics.
The Retail Footprint (Good Neighbor Pharmacy): The final point of sale is the Good Neighbor Pharmacy network, a cooperative of roughly 3,700 independently owned and operated community pharmacies. This footprint grants Electrome nationwide, immediate access to retail shelves and local patient populations.
Product Portfolio & Clinical Applications
Through the BIEL partnership, Electrome divides its market capture into consumer and clinical segments using two distinct, established product lines:
ActiPatch® (Consumer/Retail Channel): An over-the-counter (OTC) wearable device utilizing Pulsed Shortwave Therapy (PSWT) and Pulsed Electromagnetic Field (PEMF) technology. Operating at 27.12 MHz, it is marketed directly on pharmacy shelves for consumer-facing musculoskeletal pain, plantar fasciitis, and menstrual pain management.
RecoveryRx® (Clinician-Directed Channel): A clinician-prescribed, wearable PEMF system designed for clinical workflows. It is deployed for postoperative pain, edema (swelling), and chronic wound management. Clinical trials indicate a ~50% reduction in postoperative pain and a significant decrease in narcotic pain pill utilization.
Investment Highlights & Strategic Value
Immediate TAM Capture: Rather than building a retail footprint from scratch, the entry into 3,700 locations provides instant, dense geographic coverage across the U.S. and Puerto Rico.
High-Margin Hardware, Scalable Software: BIEL handles the heavy-lifting of manufacturing and regulatory compliance (where margins remain highly favorable), while Electrome layers on high-value, high-retention AI software that captures long-term patient data.
Defensible Market Position: Partnering with independent pharmacies aligns with current clinical macro-trends moving away from opioid prescription liabilities. Independent pharmacists, who lead the industry in customer satisfaction, act as trusted, hyper-local consultants actively pushing non-pharmacological, drug-free alternatives over corporate mega-chains.
So glad that I was able to buy millions of shares at .0001, .0002, etc., and enjoy the recent momentum (400% PPS surge, better than 99.9% of all stocks)! Thanks to all of the USEFUL IDIOTS that helped me get cheap shares. Keep up the good work, I'm still buying!
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
ddls
30秒前
misanthrope
2日前
toohot
2日前
NASDAQ2020
2日前
Hawk05
2日前
メールアドレスで登録
